LI_184003
|
Pages: NA
|
Mar 2019 | 760 Views
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*: |
|
Nifedipine is a drug that belongs to the class of calcium channel blocker, which interrupts the movement of calcium in the walls of the arteries. Nifedipine is used specifically to treat hypertension, arrhythmias, and angina. In addition, it has several other therapeutical applications such as ryanoids syndrome, cephalagra, and others.
Factors such as increase in geriatric population, healthcare expenditure, incidence of chronic diseases such as heart failure, arrhythmias, & hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects of the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.
The market is segmented on the basis of product, application, and region. By product, the market is bifurcated into nifedipine controlled release tablets and nifedipine extended release tablets. Based on application, the market is categorized into primary pulmonary hypertension, heart failure, ryanoids disease, cephalagra, bronchial asthma, and premature labor. By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
List of players profiled in the report
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.